Zomedica Other Current Liab vs Cash And Short Term Investments Analysis
ZOM Stock | USD 0.18 0.01 4.53% |
Zomedica Pharmaceuticals financial indicator trend analysis is more than just analyzing Zomedica Pharmaceuticals current accounting drivers to predict future trends. We encourage investors to analyze account correlations over time for multiple indicators to determine whether Zomedica Pharmaceuticals is a good investment. Please check the relationship between Zomedica Pharmaceuticals Other Current Liab and its Cash And Short Term Investments accounts. Check out Your Current Watchlist to better understand how to build diversified portfolios, which includes a position in Zomedica Pharmaceuticals Corp. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in persons.
Other Current Liab vs Cash And Short Term Investments
Other Current Liab vs Cash And Short Term Investments Correlation Analysis
The overlapping area represents the amount of trend that can be explained by analyzing historical patterns of Zomedica Pharmaceuticals Other Current Liab account and Cash And Short Term Investments. At this time, the significance of the direction appears to have no relationship.
The correlation between Zomedica Pharmaceuticals' Other Current Liab and Cash And Short Term Investments is 0.0. Overlapping area represents the amount of variation of Other Current Liab that can explain the historical movement of Cash And Short Term Investments in the same time period over historical financial statements of Zomedica Pharmaceuticals Corp, assuming nothing else is changed. The correlation between historical values of Zomedica Pharmaceuticals' Other Current Liab and Cash And Short Term Investments is a relative statistical measure of the degree to which these accounts tend to move together. The correlation coefficient measures the extent to which Other Current Liab of Zomedica Pharmaceuticals Corp are associated (or correlated) with its Cash And Short Term Investments. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when Cash And Short Term Investments has no effect on the direction of Other Current Liab i.e., Zomedica Pharmaceuticals' Other Current Liab and Cash And Short Term Investments go up and down completely randomly.
Correlation Coefficient | 0.0 |
Relationship Direction | Flat |
Relationship Strength | Insignificant |
Other Current Liab
Cash And Short Term Investments
Short Term Investments is an account in the current assets section of Zomedica Pharmaceuticals balance sheet. This account contains Zomedica Pharmaceuticals investments that will expire within one year. These investments include stocks and bonds that can be liquidated by Zomedica Pharmaceuticals Corp fairly quickly. The sum of a company's cash on hand, including bank deposits and short-term, highly liquid investments that are easily convertible to known amounts of cash.Most indicators from Zomedica Pharmaceuticals' fundamental ratios are interrelated and interconnected. However, analyzing fundamental ratios indicators one by one will only give a small insight into Zomedica Pharmaceuticals current financial condition. On the other hand, looking into the entire matrix of fundamental ratios indicators, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Your Current Watchlist to better understand how to build diversified portfolios, which includes a position in Zomedica Pharmaceuticals Corp. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in persons. At this time, Zomedica Pharmaceuticals' Selling General Administrative is very stable compared to the past year. As of the 21st of May 2024, Sales General And Administrative To Revenue is likely to grow to 1.30, while Issuance Of Capital Stock is likely to drop 0.00.
2021 | 2022 | 2023 | 2024 (projected) | Depreciation And Amortization | 1.5M | 6.7M | 6.3M | 6.6M | Interest Income | 321.1K | 2.5M | 5.6M | 5.9M |
Zomedica Pharmaceuticals fundamental ratios Correlations
Click cells to compare fundamentals
Zomedica Pharmaceuticals Account Relationship Matchups
High Positive Relationship
High Negative Relationship
Zomedica Pharmaceuticals fundamental ratios Accounts
2019 | 2020 | 2021 | 2022 | 2023 | 2024 (projected) | ||
Total Assets | 4.2M | 66.1M | 280.4M | 279.6M | 253.2M | 265.9M | |
Other Current Liab | 1.0 | 1.2M | 501.5K | 265K | 172K | 163.4K | |
Total Current Liabilities | 2.1M | 2.0M | 4.3M | 7.8M | 9.0M | 9.5M | |
Total Stockholder Equity | 2.1M | 51.1M | 270.9M | 267.4M | 240.0M | 252.0M | |
Net Debt | (510.6K) | (60.1M) | (193.6M) | (25.7M) | (10.2M) | (10.7M) | |
Retained Earnings | (52.1M) | (69.0M) | (119.4M) | (136.4M) | (170.9M) | (162.4M) | |
Cash | 510.6K | 62.0M | 195.0M | 27.4M | 13.0M | 12.3M | |
Non Current Assets Total | 2.4M | 3.3M | 80.0M | 156.1M | 153.3M | 161.0M | |
Non Currrent Assets Other | (2.4M) | 1M | 659.1K | 453K | 1.1M | 1.1M | |
Cash And Short Term Investments | 510.6K | 62.0M | 195.0M | 115.1M | 90.5M | 95.0M | |
Liabilities And Stockholders Equity | 4.2M | 66.1M | 280.4M | 279.6M | 253.2M | 265.9M | |
Other Stockholder Equity | 3.6M | 2.8M | 9.3M | 23.7M | 29.9M | 31.4M | |
Total Liab | 2.1M | 15.1M | 9.5M | 12.2M | 13.2M | 13.8M | |
Total Current Assets | 1.8M | 62.9M | 200.4M | 123.5M | 99.9M | 104.9M | |
Net Receivables | 67.6K | 146.2K | 765.5K | 1.9M | 2.2M | 2.3M | |
Common Stock Shares Outstanding | 106.3M | 364.4M | 956.5M | 979.9M | 979.9M | 1.0B | |
Other Current Assets | 1.2M | 727.8K | 1.8M | 3.8M | 2.1M | 1.4M | |
Accumulated Other Comprehensive Income | 0.0 | 459.6K | 1.7K | (843K) | 48K | 59.2K | |
Common Stock | 38.6M | 104.8M | 381.0M | 381.0M | 342.9M | 325.7M | |
Net Tangible Assets | (10.4M) | 50.7M | 194.1M | 161.6M | 185.9M | 195.1M | |
Property Plant And Equipment Net | 1.8M | 1.9M | 2.5M | 9.2M | 25.3M | 26.6M | |
Accounts Payable | 2.1M | 1.2M | 3.2M | 6.7M | 7.7M | 8.1M | |
Common Stock Total Equity | 38.6M | 459.6 | 381.0M | 381.0M | 438.1M | 460.0M | |
Retained Earnings Total Equity | (52.1M) | (69.0M) | (119.4M) | (136.4M) | (122.8M) | (116.6M) | |
Short Term Investments | 570.0K | 1.3M | 1.0M | 87.7M | 77.5M | 81.4M | |
Property Plant And Equipment Gross | 2.4M | 583.01 | 3.4M | 10.4M | 27.3M | 28.7M | |
Intangible Assets | 543.4K | 376.6K | 33.5M | 41.8M | 55.4M | 58.1M | |
Property Plant Equipment | 1.8M | 583.0K | 2.5M | 6.8M | 7.8M | 8.2M | |
Cash And Equivalents | 510.6K | 62.0M | 195.0M | 27.4M | 31.5M | 46.1M | |
Capital Surpluse | 3.6M | 14.8M | 9.3M | 23.7M | 27.2M | 28.6M | |
Net Invested Capital | (9.9M) | 51.6M | 270.9M | 267.4M | 240.0M | 130.1M |
Becoming a Better Investor with Macroaxis
Macroaxis puts the power of mathematics on your side. We analyze your portfolios and positions such as Zomedica Pharmaceuticals using complex mathematical models and algorithms, but make them easy to understand. There is no real person involved in your portfolio analysis. We perform a number of calculations to compute absolute and relative portfolio volatility, correlation between your assets, value at risk, expected return as well as over 100 different fundamental and technical indicators.Build Optimal Portfolios
Align your risk with return expectations
Check out Your Current Watchlist to better understand how to build diversified portfolios, which includes a position in Zomedica Pharmaceuticals Corp. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in persons. You can also try the Headlines Timeline module to stay connected to all market stories and filter out noise. Drill down to analyze hype elasticity.
Complementary Tools for Zomedica Stock analysis
When running Zomedica Pharmaceuticals' price analysis, check to measure Zomedica Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Zomedica Pharmaceuticals is operating at the current time. Most of Zomedica Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of Zomedica Pharmaceuticals' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Zomedica Pharmaceuticals' price. Additionally, you may evaluate how the addition of Zomedica Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.
Fundamental Analysis View fundamental data based on most recent published financial statements | |
Equity Valuation Check real value of public entities based on technical and fundamental data | |
Stocks Directory Find actively traded stocks across global markets | |
USA ETFs Find actively traded Exchange Traded Funds (ETF) in USA | |
Portfolio Optimization Compute new portfolio that will generate highest expected return given your specified tolerance for risk | |
Analyst Advice Analyst recommendations and target price estimates broken down by several categories | |
Insider Screener Find insiders across different sectors to evaluate their impact on performance | |
Idea Breakdown Analyze constituents of all Macroaxis ideas. Macroaxis investment ideas are predefined, sector-focused investing themes | |
AI Portfolio Architect Use AI to generate optimal portfolios and find profitable investment opportunities |
Is Zomedica Pharmaceuticals' industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Zomedica Pharmaceuticals. If investors know Zomedica will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Zomedica Pharmaceuticals listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (0.04) | Revenue Per Share 0.026 | Quarterly Revenue Growth 0.142 | Return On Assets (0.08) | Return On Equity (0.15) |
The market value of Zomedica Pharmaceuticals is measured differently than its book value, which is the value of Zomedica that is recorded on the company's balance sheet. Investors also form their own opinion of Zomedica Pharmaceuticals' value that differs from its market value or its book value, called intrinsic value, which is Zomedica Pharmaceuticals' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Zomedica Pharmaceuticals' market value can be influenced by many factors that don't directly affect Zomedica Pharmaceuticals' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Zomedica Pharmaceuticals' value and its price as these two are different measures arrived at by different means. Investors typically determine if Zomedica Pharmaceuticals is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Zomedica Pharmaceuticals' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.